Not all benzimidazole derivatives are microtubule destabilizing agents. (2023)

Peer-Reviewed Study · In-Ho Song; Su Jeong Park; Gyu Seong Yeom et al. · August 2023

In-Ho Song et al., 2023-08: Medicinal-chemistry paper synthesising about twenty benzimidazole analogues and reporting two that stabilise rather than destabilise microtubules; it accepts that mebendazole itself is a destabiliser.

FDA-approved drugs containing a benzimidazole ring (nocodazole, albendazole, mebendazole, etc.) are well-known microtubule-destabilizing agents.

In-Ho Song et al., 2023-08: Medicinal-chemistry paper synthesising about twenty benzimidazole analogues and reporting two that stabilise rather than destabilise microtubules; it accepts that mebendazole itself is a destabiliser. Study type: synthetic chemistry plus cell-line testing (A549, MCF-7, MRC-5). N: not applicable. Country: South Korea (Hallym University; Biometrix Technology). Dose: IC50 values 2.33-16.9 micromolar for the novel analogues NI-11 and NI-18, not for mebendazole. Funder: not stated in the record. Declared conflicts: 'The authors declare that they have no known competing financial interests…'. PARTLY because the paper's finding is that not all benzimidazoles destabilise microtubules; that finding concerns new synthetic analogues, not mebendazole, which the authors still class as a destabiliser. Study type: lab.